Mark Ellul

Mark Ellul

Auto-generated profile, based on publicly available information

Mark Ellul

Institute of Infection, Veterinary and Ecological Science, University of Liverpool, Liverpool, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CSCristiane N. Soares
Cristiane N. Soares
PBPatrícia Brasil
Patrícia Brasil
RCRaquel Medialdea Carrera
Raquel Medialdea Carrera
PSPatricia Sequeira
Patricia Sequeira
AFAna Bispo de Filippis
Ana Bispo de Filippis
TSTom Solomon
Tom Solomon

12 February 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RMRavi Mehta
Ravi Mehta
CSCristiane Nascimento Soares
Cristiane Nascimento Soares
RMRaquel Medialdea-Carrera
Raquel Medialdea-Carrera
MEMark Ellul
Mark Ellul
MSMarcus Tulius Texeira Da Silva
Marcus Tulius Texeira Da Silva
TSTom Solomon
Tom Solomon
During 2015–16 Brazil experienced the largest epidemic of Zika virus ever reported. This arthropod-borne virus (arbovirus) has been linked to Guillain-Barré syndrome (GBS) in adults but other neurological associations are uncertain. Chikungunya virus has caused outbreaks in Brazil since 2014 but associated neurological disease has rarely been reported here. We investigated adults with acute neurological disorders for Zika, chikungunya and dengue, another arbovirus circulating in Brazil. We studied adults who had developed a new neurological condition following suspected Zika virus infection between 1st November 2015 and 1st June 2016. Cerebrospinal fluid (CSF), serum, and urine were tested for evidence of Zika, chikungunya, and dengue viruses. Of 35 patients studied, 22 had evidence of recent arboviral infection. Twelve had positive PCR or IgM for Zika, five of whom also had evidence for chikungunya, three for dengue, and one for all three viruses. Five of them presented with GBS; seven had presentations other than GBS, including meningoencephalitis, myelitis, radiculitis or combinations of these syndromes. Additionally, ten patients positive for chikungunya virus, two of whom also had evidence for dengue virus, presented with a similar range of neurological conditions. Zika virus is associated with a wide range of neurological manifestations, including central nervous system disease. Chikungunya virus appears to have an equally important association with neurological disease in Brazil, and many patients had dual infection. To understand fully the burden of Zika we must look beyond GBS, and also investigate for other co-circulating arboviruses, particularly chikungunya. During 2015–16, Brazil experienced the largest outbreak of the mosquito-borne Zika virus ever reported and saw a subsequent increase in cases of Guillain-Barré syndrome (GBS), a disorder of the peripheral nervous system (nerves outside the brain and spinal cord) that can result in paralysis and sometimes death. In this assessment of adults presenting with suspected Zika virus-associated neurological disease in Rio de Janeiro, Brazil, we add to the growing body of evidence linking Zika to a wider range of neurological disease, including disease of the central nervous system (brain and spinal cord). We also show that many patients initially thought to have neurological disease associated with Zika virus were in fact infected with chikungunya virus, another arthropod-borne virus (arbovirus) that is also associated with a wide range of neurological disease. Importantly, many patients had evidence of infection with more than one virus. We discuss the challenges in diagnosing the infections and how different body fluid samples can be used to help facilitate this. Our results suggest that clinicians and public health officials must look beyond GBS if we are to understand fully the disease burden of Zika virus. In addition, we highlight the need to investigate patients with acute neurological syndromes for other co-circulating arboviruses, particularly chikungunya.

22 September 2014 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MZMichael S Zandi
Michael S Zandi
RPR W. Paterson
R W. Paterson
MEMark A Ellul
Mark A Ellul
LJLeslie Jacobson
Leslie Jacobson
AAAdam Al-Diwani
Adam Al-Diwani
AVAngela Vincent
Angela Vincent
Objective There are now a large number of requests for N-methyl-d-aspartate receptor autoantibody (NMDAR-Ab) tests, and it is important to assess the clinical relevance of all results, particularly when they are reported as ‘Low Positive’. Methods The clinical data of 56 patients found Positive or Low Positive by the Oxford live cell-based assay were reviewed. An autoimmune basis for the condition was assigned as ‘Definite’, ‘Possible’ or ‘Unlikely’. The number of core features (encephalopathy, psychiatric, cognitive, epileptic, extrapyramidal and inflammatory cerebrospinal fluid (CSF)) was tabulated. Results Twenty-five (44.6%) patients had a Definite NMDAR-Ab encephalitis (eight ovarian teratomas, one Hodgkin's lymphoma), 18 (32.1%) a Possible NMDAR-Ab encephalitis and 13 (23.2%) an Unlikely autoimmune syndrome. Serum NMDAR-Ab levels were higher in patients with tumours. Positive NMDAR-Abs were found not only in patients with three or more core features and a Definite syndrome, but also in five patients classified as Possible. Conversely, Low Positive NMDAR-Abs were present in 7 Definite cases as well as in 13 Possible cases. Unlikely patients had mainly Low Positive antibodies and fewer core features. CSF NMDAR-Abs, only available in 11 pairs and at varying time points, broadly related to serum levels and were Positive in 3/3 patients with tumours but in only 2/5 Definite patients, and none of the Possible or Unlikely cases. Interpretation Using live cell-based assays, Positive and Low Positive antibodies can be of clinical significance. The number of core clinical features should help to select those patients in whom an immunotherapy intervention might be considered, irrespective of the antibody level.

3 June 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
JRJonathan P Rogers
Jonathan P Rogers
CWCameron J Watson
Cameron J Watson
JBJames Badenoch
James Badenoch
BCBenjamin Cross
Benjamin Cross
MBMatthew Butler
Matthew Butler
ARAlasdair G Rooney
Alasdair G Rooney
There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2. In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and estimate point prevalences for neurological and neuropsychiatric manifestations. We searched MEDLINE, Embase, PsycINFO and CINAHL up to 18 July 2020 for randomised controlled trials, cohort studies, case-control studies, cross-sectional studies and case series. Studies reporting prevalences of neurological or neuropsychiatric symptoms were synthesised into meta-analyses to estimate pooled prevalence. 13 292 records were screened by at least two authors to identify 215 included studies, of which there were 37 cohort studies, 15 case-control studies, 80 cross-sectional studies and 83 case series from 30 countries. 147 studies were included in the meta-analysis. The symptoms with the highest prevalence were anosmia (43.1% (95% CI 35.2% to 51.3%), n=15 975, 63 studies), weakness (40.0% (95% CI 27.9% to 53.5%), n=221, 3 studies), fatigue (37.8% (95% CI 31.6% to 44.4%), n=21 101, 67 studies), dysgeusia (37.2% (95% CI 29.8% to 45.3%), n=13 686, 52 studies), myalgia (25.1% (95% CI 19.8% to 31.3%), n=66 268, 76 studies), depression (23.0% (95% CI 11.8% to 40.2%), n=43 128, 10 studies), headache (20.7% (95% CI 16.1% to 26.1%), n=64 613, 84 studies), anxiety (15.9% (5.6% to 37.7%), n=42 566, 9 studies) and altered mental status (8.2% (95% CI 4.4% to 14.8%), n=49 326, 19 studies). Heterogeneity for most clinical manifestations was high. Neurological and neuropsychiatric symptoms of COVID-19 in the pandemic’s early phase are varied and common. The neurological and psychiatric academic communities should develop systems to facilitate high-quality methodologies, including more rapid examination of the longitudinal course of neuropsychiatric complications of newly emerging diseases and their relationship to neuroimaging and inflammatory biomarkers.

11 August 2015 in BMJ
Verified
Journal Article
Closed access
PDF file
MEMark A Ellul
Mark A Ellul
SGSantosh A Gholkar
Santosh A Gholkar
TCTimothy J Cross
Timothy J Cross

1 March 2016 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MEMark A. Ellul
Mark A. Ellul
MGMichael J. Griffiths
Michael J. Griffiths
AIAnand Iyer
Anand Iyer
SAShivaram Avula
Shivaram Avula
SDSylviane Defres
Sylviane Defres
RKRachel Kneen
Rachel Kneen
We report a 3-year-old boy with anti-N-methyl-D-aspartate receptor encephalitis with a typical syndrome of movement disorder and encephalopathy and evidence of herpes simplex virus (HSV) type 1 infection on brain biopsy. HSV type 1 infection and anti-N-methyl-D-aspartate receptor encephalitis are temporally linked in some cases: this case suggests that prodromal HSV type-1 infection may be clinically subtle and easily missed.